Elan Corporation, plc ELN (Elan) today announced that its Board
of Directors, after careful review and consideration and with the
assistance of its executive management team as well as outside financial
and legal advisors, has determined that privately held investment firm
Royalty Pharma's offer, through its shell subsidiary Echo Pharma
Acquisition Limited, to acquire all of the shares of Elan for $11.25 or
less per share, substantially undervalues the company.
Commenting specifically, Mr. Robert A. Ingram, Chairman of Elan
Corporation, plc, added, “The offer from Royalty Pharma grossly
undervalues Elan's current business platform and our future prospects.
As a result the Board unanimously and without reservation rejected the
offer.”
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in